PacBio Narrows 2026 Revenue Guidance to $155M-$160M

The genomics company reiterated its 2028 cash-flow breakeven target while lowering its operating expense outlook.

Updated on Nov. 6, 2026 in Biotech

PacBio Narrows 2026 Revenue Guidance to $155M-$160M

PacBio narrowed its 2026 revenue guidance to $155 million to $160 million and reiterated its goal of reaching cash-flow breakeven in 2028. The company also lowered its operating expense outlook to $203 million to $207 million.

Why it matters

PacBio attributed its outlook to inconsistent academic and government funding in the Americas and a slow recovery in China. Higher memory costs and expenses tied to the Vega manufacturing transition have also pressured gross margin.

PacBio expects to finish 2026 with $175 million to $185 million in cash, and more than half of Revio consumable revenue came from customers using SPRQ-Nx chemistry. The company has not stated when academic and government funding in the Americas or demand in China will stabilize.

The players

PacBio

Pacific Biosciences, a genomics company that develops long-read DNA sequencing systems, including the Revio and Vega platforms.

The details

More than half of PacBio's Revio consumable revenue came from customers using its SPRQ-Nx chemistry. Higher memory costs and expenses tied to the Vega manufacturing transition pressured gross margin during the period.

2026: PacBio's narrowed revenue guidance and expected year-end cash position apply to this fiscal year.
2028: PacBio's target for reaching cash-flow breakeven.

The Tech Race

PacBio's revenue depends heavily on consumables for its Revio platform, with more than half of that consumable revenue coming from SPRQ-Nx chemistry users. The company's outlook shows how much its sequencing business still relies on sustained academic, government, and international demand.

For readers following genomic research tools, PacBio's guidance signals that sequencing budgets at academic and government labs may remain uneven in 2026. Companies relying on its platforms may face continued pricing and availability pressure tied to these funding conditions.

The takeaway

PacBio's guidance points to a longer path to profitability that depends on funding conditions outside its direct control. Readers tracking genomics companies should watch for updates on academic funding and China demand as indicators of recovery.